Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-07-07

Clinical Trial Update: Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication [Phase 2]

View source ↗

Summary

Phase 2 dose-finding study assessing safety and efficacy of NV1FGF in patients with intermittent claudication due to peripheral arterial occlusive disease has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NV1FGF (NV1FGF)

Snippet

Sponsor: Sanofi | Conditions: Peripheral Arterial Occlusive Disease | Phase 2 | Status: COMPLETED